Spyre Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Spyre Therapeutics Inc 's ROA in the second quarter of 2026?
Spyre Therapeutics Inc recorded a cumulative net loss of $-179 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -19.55%.

However, within the Healthcare sector 371 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3601, from total ROA ranking in the first quarter of 2026 at 4190.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	117.69 %	34.08 %	100.28 %	19.83 %	23.57 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-179	-179	-155	-149	-207
Return On Assets (TTM)	-19.55 %	-23.72 %	-21.92 %	-26.82 %	-38.69 %
SYRE's Total Ranking	# 3601	# 4190	# 3698	# 3922	# 4033
Total Assets (TTM) in million	1,173	764	1,219	505	539
Seq. Total Assets Change	53.54 %	-37.31 %	141.51 %	-6.35 %	-5.43 %
Seq. Net Income Change	-	-	-	-	-

SYRE's 5 Years Annual ROA >> Back to SYRE Management Effectiveness >> Compare SYRE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 135
Sector	# 372
Overall	# 3470

Return On Assets Statistics
High	Average	Low
-22.23 %	-67.09 %	-237.68 %
(Jun 30 2026)		(Jun 30 2023)

Financial Statements
Spyre Therapeutics Inc 's Assets	$ 1,173 million	SYRE's Balance sheet
Spyre Therapeutics Inc 's Income	$ -36 million	Quarterly SYRE's Income Statement
SYRE's Income by Division		See SYRE's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	27.82 %	77.99 %	399.22 %	-36.26 %	-32.18 %
Total Assets in million	778	608	342	68	107
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-155	-208	-339	-84	-66
Annual Return On Assets	-19.95 %	-34.19 %	-99.1 %	-122.4 %	-61.24 %

SYRE's 5 Years Annual ROA >> Back to SYRE Management Effectiveness >> Compare SYRE ROA to its Competitors

More Return On Assets Ratios
SYRE's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SYRE's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SYRE's Competitors
Subscribers only: Roa for Spyre Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for SYRE's Customers

You may also want to know
SYRE's Roi	SYRE's Inventory Turnover Ratio	SYRE's Growth Rates	SYRE's Dividend Comparisons
	SYRE's Profitability Ratios	SYRE's Asset Turnover Ratio	SYRE's Dividend Growth
SYRE's Roe	SYRE's Valuation Ratios	SYRE's Financial Strength Ratios	SYRE's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-02T17:47:53+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.